CoChat

Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases

Open access

The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.

Abstract

Neurodegenerative diseases such as Alzheimer’s disease have proven resistant to new treatments. The complexity of neurodegenerative disease mechanisms can be highlighted by accumulating evidence for a role for a growth factor, progranulin (PGRN). PGRN is a glycoprotein encoded by the GRN/Grn gene with multiple cellular functions, including neurotrophic, anti-inflammatory and lysosome regulatory properties. Mutations in the GRN gene can lead to frontotemporal lobar degeneration (FTLD), a cause of dementia, and neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disease. Both diseases are associated with loss of PGRN function resulting, amongst other features, in enhanced microglial neuroinflammation and lysosomal dysfunction. PGRN has also been implicated in Alzheimer’s disease (AD). Unlike FTLD, increased expression of PGRN occurs in brains of human AD cases and AD model mice, particularly in activated microglia. How microglial PGRN might be involved in AD and other neurodegenerative diseases will be discussed. A unifying feature of PGRN in diseases might be its modulation of lysosomal function in neurons and microglia. Many experimental models have focused on consequences of PGRN gene deletion: however, possible outcomes of increasing PGRN on microglial inflammation and neurodegeneration will be discussed. We will also suggest directions for future studies on PGRN and microglia in relation to neurodegenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells8030230

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Summary of possible PGRN mechanisms in Alzheimer’s disease, FTLD and NCL. It is hypothesized that loss of PGRN, not increased expression that contribute to Alzheimer’s pathology.
Figure 1 Summary of possible PGRN mechanisms in Alzheimer’s disease, FTLD and NCL. It is hypothesized that loss of PGRN, not increased expression that contribute to Alzheimer’s pathology.CC BY · PubMed Central
Figure 2 Immunohistochemical localization of PGRN in human temporal cortex. Sections were double-stained with antibody to PGRN (R&D Systems, AF2420) (purple) and the microglia marker IBA-1 (Wako, 019-19741) (brown). The patterns of staining in neurons (blue arrows) and microglia (red arrows) in cells with positive staining for IBA-1 can be seen (Panels A and B). Panel C shows accumulation of microglia (brown) with extracellular PGRN deposits around an amyloid plaque. (A) Low pathology control case. (B) High pathology control case. (C) Alzheimer’s disease case. Staining patterns suggest localization to intracellular vacuoles though plaque staining patterns suggest extracellular aggregates of PGRN.
Figure 2 Immunohistochemical localization of PGRN in human temporal cortex. Sections were double-stained with antibody to PGRN (R&D Systems, AF2420) (purple) and the microglia marker IBA-1 (Wako, 019-19741) (brown). The patterns of staining in neurons (blue arrows) and microglia (red arrows) in cells with positive staining for IBA-1 can be seen (Panels A and B). Panel C shows accumulation of microglia (brown) with extracellular PGRN deposits around an amyloid plaque. (A) Low pathology control case. (B) High pathology control case. (C) Alzheimer’s disease case. Staining patterns suggest localization to intracellular vacuoles though plaque staining patterns suggest extracellular aggregates of PGRN.CC BY · PubMed Central
Figure 3 Some Features of PGRN, microglia and Alzheimer’s disease. (A) Confocal image of PGRN positive (green) accumulations within a CD45 positive microglia in a human AD brain. (B) Intracellular processing of Grn to PGRN and granulins. (C) The adjacent diagrams suggests how features identified in vivo and in vitro might interact and be involved in PGRN function in AD. There are unanswered questions about the interaction of proteins with PGRN intracellularly and with secreted PGRN. The direction of interaction of PGRN between microglia and neurons is unresolved. The diagram represents PGRN as accumulations as seen in panel A but is believed to at least be present as dimers. The final unresolved issue is whether excess of PGRN precipitates Alzheimer’s disease pathology or whether it is a deficiency of PGRN or loss of function that has this effect.
Figure 3 Some Features of PGRN, microglia and Alzheimer’s disease. (A) Confocal image of PGRN positive (green) accumulations within a CD45 positive microglia in a human AD brain. (B) Intracellular processing of Grn to PGRN and granulins. (C) The adjacent diagrams suggests how features identified in vivo and in vitro might interact and be involved in PGRN function in AD. There are unanswered questions about the interaction of proteins with PGRN intracellularly and with secreted PGRN. The direction of interaction of PGRN between microglia and neurons is unresolved. The diagram represents PGRN as accumulations as seen in panel A but is believed to at least be present as dimers. The final unresolved issue is whether excess of PGRN precipitates Alzheimer’s disease pathology or whether it is a deficiency of PGRN or loss of function that has this effect.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 159 references

Cited by

See all 73

Metadata

Authors
Mendsaikhan, A., Tooyama, I., & Walker, D. G.
Affiliations
Shiga University of Medical Science (JP)
Corresponding author
Mendsaikhan, Anarmaa
Venue
Cells
Publisher
MDPI AG
Published
2019-03-11
Volume
8
Issue
3
Pages
230
ISSN
2073-4409 (ISSN-L)
OpenAlex
W2920995467
Cited by
72
References
159
Citations by year
2026: 5 · 2025: 9 · 2024: 14 · 2023: 9 · 2022: 13 · 2021: 12 · 2020: 6 · 2019: 3
FWCI
0.88
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Japan Society for the Promotion of Science (26290022)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
progranulin, microglia, Alzheimer's disease, neurodegenerative diseases, frontotemporal lobar degeneration, neuronal ceroid lipofuscinosis, lysosomal dysfunction, neuroinflammation, anti-inflammatory activity, neurotrophic factors
MeSH terms
Progranulins, Alzheimer Disease, Animals, Disease Models, Animal, Humans, Lysosomes, Microglia, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases. https://app.cochat.ai/papers/10.3390/cells8030230
The paper
Mendsaikhan, A., Tooyama, I., & Walker, D. G. (2019). Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases. Cells. https://doi.org/10.3390/cells8030230

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.